v3.26.1
Interim Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Net sales $ 1,381 $ 1,368
Cost of goods sold 1,169 1,132
Gross profit 212 236
Selling, general, and administrative expense 147 123
Research and development expense 26 27
Restructuring, asset-related, and other charges 13 33
Total other operating expenses 186 183
Equity in earnings of affiliates 8 8
Interest expense, net (69) (66)
Loss on extinguishment of debt (9) 0
Other income, net 22 5
Loss before income taxes (22) 0
Provision for income taxes (7) (5)
Net loss (29) (5)
Net loss attributable to Chemours $ (29) $ (5)
Per share data    
Basic (loss) earnings per share of common stock [1] $ (0.19) $ (0.03)
Diluted (loss) earnings per share of common stock [1],[2] $ (0.19) $ (0.03)
[1] Figures may not recalculate exactly due to rounding. Basic and diluted earnings per share are calculated based on unrounded numbers.
[2] In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS, as their inclusion would have an anti-dilutive effect. As such, with respect to the measure of diluted EPS, the impact of 819,728 and 491,194 potentially dilutive securities is excluded from the calculation for the three months ended March 31, 2026 and March 31, 2025, respectively.